Brief: MaxCyte Q3 Revenue USD 8.2 Million Vs. IBES Estimate USD 7.37 Million
06/11/2024 21:05
Nov 06 (Reuters) - MaxCyte Q3 cash & investments USD 196.6 million. * Q3 gross profit USD 6.2 million * Q3 operating expenses USD 20.3 million * Q3 adjusted EBITDA USD -13 million * Q3 net income USD -11.6 million
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026